From: Clinical and laboratory prognosticators of atrophic papulosis (Degos disease): a systematic review
All Patients | MAP | BAP | |
---|---|---|---|
Number of patients | 105 | 67 | 38 |
Male/female (ratio) | 47/58 (1:1.2) | 35/32 (1.1:1) | 12/26 (1:2.2) |
Mean age of cutaneous onset (stdev) | 35 (0–75) | 35 (0–75) | 35 (0.2–63) |
Familial occurrence, n (%) | 5/22 (22.7) | 2/14 (14.3) | 3/8 (37.5) |
Mortality, n (%) | N/A | 48/67 (71.6%) | N/A |
Mean follow up time of study | 2.55 (3.01) | 2.20 (2.69) | 3.36 (3.53) |
Distribution of lesions, n (%) | |||
Generalized | 95/104 (91.3) | 61/66 (92.4) | 34/38 (89.5) |
Localized | 9/104 (8.7) | 5/66 (7.6) | 4/38 (10.5) |
Primary or secondary Degos, n (%) | |||
Primary | 94/105 (89.5) | 63/67 (94) | 31/38 (81.6) |
Secondary | 11/105 (10.5) | 4/67 (6.0) | 7/38 (18.4) |
Dermatomyositis | 2/105 (1.9) | 0/67 (0) | 2/38 (5.3) |
Relapsing polychondritis | 1/105 (1) | 0/67 (0) | 1/38 (2.6) |
Rheumatoid arthritis | 1/105 (1) | 1/67 (1.5) | 0/38 (0) |
Systemic lupus erythematosus | 8/105 (7.6) | 2/67 (3) | 6/38 (15.8) |
Treatments, n (%) | |||
Anticoagulant | 20/93 (21.5) | 19/63 (30.2) | 1/30 (3.3) |
Antiplatelet (Single) | 29/93 (31.2) | 21/63 (33.3) | 8/30 (26.7) |
Antiplatelet (Dual) | 19/93 (20.4) | 14/63 (22.2) | 5/30 (16.7) |
Biologics | |||
Eculizumab | 8/93 (8.6) | 8/63 (12.7) | 0/30 (0) |
Infliximab | 3/93 (3.2) | 3/63 (4.8) | 0/30 (0) |
Natalizumab | 1/93 (1.1) | 1/63 (1.6) | 0/30 (0) |
Rituximab | 2/93 (2.2) | 2/63 (3.17) | 0/30 (0) |
Corticosteroids (topical and oral) | 39/93 (41.2) | 31/63 (49.2) | 8/30 (26.7) |
Immunomodulators | |||
Aminosalicylates | 1/93 (1.1) | 1/63 (1.6) | 0/30 (0) |
Azathioprine | 2/93 (2.2) | 1/63 (1.6) | 1/30 (3.3) |
Cyclosporin A | 3/93 (3.2) | 2/63 (3.2) | 1/30 (3.3) |
IVIg | 13/93 (14) | 11/63 (17.5) | 2/30 (6.6) |
Methotrexate | 4/93 (4.3) | 2/63 (3.2) | 2/30 (6.6) |
Tacrolimus | 2/93 (2.2) | 1/63 (1.6) | 1/30 (3.3) |
Thalidomide | 1/93 (1.1) | 1/63 (1.6) | 0/30 (0) |
Prostaglandin | 2/93 (2.2) | 1/63 (1.6) | 1/30 (3.3) |
Steroid sparing agents | |||
Cyclosporine | 2/93 (2.2) | 2/63 (3.2) | 0/30 (0) |
Dapsone | 2/93 (2.2) | 1/63 (1.6) | 1/30 (3.3) |
Others | |||
Cyclophosphamide | 7/93 (7.5) | 7/63 (11.1) | 0/30 (0) |
Pentoxifylline | 9/93 (9.7) | 6/63 (9.52) | 3/30 (10) |
No Treatment | 7/93 (7.5) | 1/63 (1.6) | 6/30 (20) |
Not Reported | 12/93 (12.9) | 4/63 (6.4) | 8/30 (26.7) |
Abnormal labs, n (%) | |||
ESR/CRP | 14/76 (18.4) | 13/48 (27.1) | 1/28 (3.6) |
ANA | 10/75 (13.3) | 4/46 (8.7) | 6/29 (20.1) |
Patient geographic distribution, n (%) | |||
Asia | 33/105 (31.4) | 23/67 (34.3) | 10/38 (26.3) |
North America | 28/105 (26.7) | 17/67 (25.4) | 11/38 (28.9) |
South America | 2/105 (1.9) | 2/67 (3) | 0/38 (0) |
Europe | 38/105 (36.2) | 22/67 (32.8) | 16/38 (42.1) |
Africa | 0/105 (0) | 0/67 (0) | 0/38 (0) |
Australia | 4/105 (3.8) | 3/67 (4.5) | 1/38 (2.6) |